drugset / Trial / NCT03013387
Dosimetry Guided PRRT With 90Y-DOTATOC
Phase 2
Withdrawn
Sue O'Dorisio
National Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.
Timeline
- Start
- 2017-01
- Primary completion
- 2018-10
- Completion
- 2019-10
Outcome
Outcome not reported
Stopped: “This project has undergone a significant amount of updates and has been resubmitted under IRB# 201708778”